258 related articles for article (PubMed ID: 15094159)
1. Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion.
Schagen FH; Ossevoort M; Toes RE; Hoeben RC
Crit Rev Oncol Hematol; 2004 Apr; 50(1):51-70. PubMed ID: 15094159
[TBL] [Abstract][Full Text] [Related]
2. Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy.
Jooss K; Chirmule N
Gene Ther; 2003 Jun; 10(11):955-63. PubMed ID: 12756416
[TBL] [Abstract][Full Text] [Related]
3. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms.
Bessis N; GarciaCozar FJ; Boissier MC
Gene Ther; 2004 Oct; 11 Suppl 1():S10-7. PubMed ID: 15454952
[TBL] [Abstract][Full Text] [Related]
4. Adenoviral vectors for liver-directed gene therapy.
Connelly S
Curr Opin Mol Ther; 1999 Oct; 1(5):565-72. PubMed ID: 11249663
[TBL] [Abstract][Full Text] [Related]
5. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.
Roberts DM; Nanda A; Havenga MJ; Abbink P; Lynch DM; Ewald BA; Liu J; Thorner AR; Swanson PE; Gorgone DA; Lifton MA; Lemckert AA; Holterman L; Chen B; Dilraj A; Carville A; Mansfield KG; Goudsmit J; Barouch DH
Nature; 2006 May; 441(7090):239-43. PubMed ID: 16625206
[TBL] [Abstract][Full Text] [Related]
6. Neonatal cotton rats do not exhibit destructive immune responses to adenoviral vectors.
Zepeda M; Wilson JM
Gene Ther; 1996 Nov; 3(11):973-9. PubMed ID: 8940637
[TBL] [Abstract][Full Text] [Related]
7. A mouse model of arterial gene transfer: antigen-specific immunity is a minor determinant of the early loss of adenovirus-mediated transgene expression.
Vassalli G; Agah R; Qiao R; Aguilar C; Dichek DA
Circ Res; 1999 Oct; 85(9):e25-32. PubMed ID: 10532959
[TBL] [Abstract][Full Text] [Related]
8. The controversial role of adenoviral-derived vectors in gene therapy programs: where do we stand?
Romano G
Drug News Perspect; 2006 Mar; 19(2):99-106. PubMed ID: 16628265
[TBL] [Abstract][Full Text] [Related]
9. An immunomodulatory procedure that stabilizes transgene expression and permits readministration of E1-deleted adenovirus vectors.
Kuzmin AI; Galenko O; Eisensmith RC
Mol Ther; 2001 Mar; 3(3):293-301. PubMed ID: 11273770
[TBL] [Abstract][Full Text] [Related]
10. Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway.
Scaria A; St George JA; Gregory RJ; Noelle RJ; Wadsworth SC; Smith AE; Kaplan JM
Gene Ther; 1997 Jun; 4(6):611-7. PubMed ID: 9231078
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses.
Mok H; Palmer DJ; Ng P; Barry MA
Mol Ther; 2005 Jan; 11(1):66-79. PubMed ID: 15585407
[TBL] [Abstract][Full Text] [Related]
12. Germline incorporation of a replication-defective adenoviral vector in mice does not alter immune responses to adenoviral vectors.
Camargo FD; Huey-Louie DA; Finn AV; Sassani AB; Cozen AE; Moriwaki H; Schneider DB; Agah R; Dichek DA
Mol Ther; 2000 Nov; 2(5):496-504. PubMed ID: 11082323
[TBL] [Abstract][Full Text] [Related]
13. Innate immune response induced by gene delivery vectors.
Sakurai H; Kawabata K; Sakurai F; Nakagawa S; Mizuguchi H
Int J Pharm; 2008 Apr; 354(1-2):9-15. PubMed ID: 17640834
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy progress and prospects: adenoviral vectors.
St George JA
Gene Ther; 2003 Jul; 10(14):1135-41. PubMed ID: 12833122
[TBL] [Abstract][Full Text] [Related]
15. Engineered adenovirus serotypes for overcoming anti-vector immunity.
Dharmapuri S; Peruzzi D; Aurisicchio L
Expert Opin Biol Ther; 2009 Oct; 9(10):1279-87. PubMed ID: 19645630
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of costimulation allows for repeated systemic administration of adenoviral vector in rhesus monkeys.
Haegel-Kronenberger H; Haanstra K; Ziller-Remy C; Ortiz Buijsse AP; Vermeiren J; Stoeckel F; Van Gool SW; Ceuppens JL; Mehtali M; De Boer M; Jonker M; Boon L
Gene Ther; 2004 Feb; 11(3):241-52. PubMed ID: 14737083
[TBL] [Abstract][Full Text] [Related]
17. Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo.
Muruve DA; Cotter MJ; Zaiss AK; White LR; Liu Q; Chan T; Clark SA; Ross PJ; Meulenbroek RA; Maelandsmo GM; Parks RJ
J Virol; 2004 Jun; 78(11):5966-72. PubMed ID: 15140994
[TBL] [Abstract][Full Text] [Related]
18. The impact of antigen expression in antigen-presenting cells on humoral immune responses against the transgene product.
Feng Y; Jacobs F; Van Craeyveld E; Lievens J; Snoeys J; Van Linthout S; De Geest B
Gene Ther; 2010 Feb; 17(2):288-93. PubMed ID: 19759564
[TBL] [Abstract][Full Text] [Related]
19. Respective roles of TNF-alpha and IL-6 in the immune response-elicited by adenovirus-mediated gene transfer in mice.
Benihoud K; Esselin S; Descamps D; Jullienne B; Salone B; Bobé P; Bonardelle D; Connault E; Opolon P; Saggio I; Perricaudet M
Gene Ther; 2007 Mar; 14(6):533-44. PubMed ID: 17109009
[TBL] [Abstract][Full Text] [Related]
20. Use of multiply deleted adenovirus vectors to probe adenovirus vector performance and toxicities.
Amalfitano A
Curr Opin Mol Ther; 2003 Aug; 5(4):362-6. PubMed ID: 14513678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]